Obermatt
See Similar Stocks →

Contineum Therapeutics

NSQ:CTNM · US21217B1008
PharmaceuticalsSmall

360° View

80
Price/Sales12
Price/Earnings63
Price/Book52
Dividend Yield1
Revenue Growth1
Profit Growth33
Capital Growth94
TSR 52w95
Leverage83
Liquidity29
Refinancing51
Combined82
Analyst Opinions50
Pro Holdings71
Opinion Changes50
Market Pulse57

Profile

CountryUSA
IndustryPharmaceuticals
SizeSmall
TypePublic Company
ExchangeNASDAQGS
Founded2009
Employees54
Websitecontineum-tx.com
ISINUS21217B1008
Last UpdateApr 2, 2026
Index & Theme
ImmunologyPain ManagementNeurologyCentral Nervous SystemRespiratoryInflammationNeuroscienceBiotechnologyHealth CarePharmaceuticalTherapeutics

Description

Contineum Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company’s efforts on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. The co…

Analysis

Contineum Therapeutics's 360° View rank of 80 places it among the strongest overall — better than 80% of its true peers.

It's a growth standout (91) and on the expensive side (32). On safety it is financially sound (65), and the market shows favorable sentiment (67). Taken together, its Combined rank of 82 reads as among the strongest overall.

360° rank · history

1007550250
80
2026

All-time high

81

Mar 2026

All-time low

80

Jun 2026

Average rank

81

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
12
—
—
—
Price/Earnings
63
—
—
—
Price/Book
52
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
32
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Contineum Therapeutics with its peers
Lexicon Pharmaceuticals
NAQ:LXRX
28
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Kura Oncology
NSQ:KURA
30
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
PowerBank
NEO:SUNN
42
CountryCanada
IndustryConstruction & Engineering
SizeSmall
Full Stock Analysis →
Verrica Pharmaceuticals
NAQ:VRCA
55
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Enanta Pharmaceuticals
NSQ:ENTA
62
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Cardiol Therapeutics
TOR:CRDL
81
CountryCanada
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →